File No. 211113
FILE INO. ZIIIIO

Committee Item	No.	
Board Item No.	23	

COMMITTEE/BOARD OF SUPERVISORS

AGENDA PACKET CONTENTS LIST

Committee:		Date:	
Board of Super	visors Meeting	Date:	November 2, 2021
Cmte Board			
Re	esolution dinance gislative Digest lidget and Legislative Analyst buth Commission Report roduction Form epartment/Agency Cover Lette DU ant Information Form ant Budget libcontract Budget ontract/Agreement rm 126 – Ethics Commission ward Letter eplication liblic Correspondence	-	
OTHER			
Prepared by: <u>L</u> Prepared by: <u></u>	_isa Lew	Date: Date:	October 29, 2021

Introduction Form

By a Member of the Board of Supervisors or the Mayor

I hereby submit the following item for introduction (select only one):

Time stamp or meeting date

	1. For reference to Committee. (An Ordinance, Resolution, Motion, or Charter Amendment)
	2. Request for next printed agenda Without Reference to Committee.
\boxtimes	3. Request for hearing on a subject matter at Committee.
	4. Request for letter beginning "Supervisor inquires"
	5. City Attorney request.
	6. Call File No. from Committee.
	7. Budget Analyst request (attach written motion).
	8. Substitute Legislation File No.
	9. Reactivate File No.
	10. Question(s) submitted for Mayoral Appearance before the BOS on
Please	check the appropriate boxes. The proposed legislation should be forwarded to the following: Small Business Commission Youth Commission Ethics Commission
	☐ Planning Commission ☐ Building Inspection Commission
Note: 1	For the Imperative Agenda (a resolution not on the printed agenda), use a Imperative Form.
Sponso	r(s):
Clerk	of the Board
Subjec	t:
McKes	g - Committee of the Whole - Existing Litigation - AmerisourceBergen Corp., Cardinal Health, Inc., and son Corp City to Receive \$27 Million to \$50 Million - Johnson & Johnson - City to Receive \$6 Million to Ulion - November 2, 2021

The text is listed below or attached:

Hearing of the Board of Supervisors sitting as a Committee of the Whole on November 2, 2021, at 3:00 p.m., to hold a public hearing to consider proposed Ordinances (File Nos. 211071 and 211072) regarding existing litigation relating to the partial settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against three large distributors of prescription opioids (AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation) for abatement funds in the range of \$27 million to \$50 million to be paid over 18 years, entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen

Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc. N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation, and the partial settlement of the lawsuit filed on behalf of the City and County of San Francisco and the People of the State of California against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., for abatement funds in the range of \$6 million to \$11 million to be paid over nine years, entitled The City and County of San Francisco and the People of the State of California v. Purdue Pharma L.P., Richard S. Sackler, Jonathan D. Sackler, Mortimer D.A. Sackler, Kathe A. Sackler, Ilene Sackler Lefcourt, Beverly Sackler, Theresa Sackler, David A. Sackler, Trust for the Benefit of Members of the Raymond Sackler Family, Rhodes Pharmaceuticals L.P., Cephalon, Inc., Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Endo International Plc, Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., Insys Therapeutics, Inc., Mallinckrodt Plc, Mallinckrodt LLC, Allergan Plc F/K/A Actavis Plc, Watson Pharmaceuticals, Inc., N/K/A Actavis, Inc., Watson Laboratories, Inc., Actavis LLC, Actavis Pharma, Inc. F/K/A/ Watson Pharma, Inc., AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation; scheduled pursuant to Motion Nos. M21-148 (File No. 211112) and M21-149 (File No. 211114), approved on October 26, 2021.

Signature of Sponsoring Supervisor:	
-	

For Clerk's Use Only: